18 and older, any sex, with COVID-19 or Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mechanical Ventilation or Death EndpointPrimary· Day 14
Number of participants that progressed to mechanical ventilation or death within the first 14 days of enrollment.
Group
Value
95% CI
COVID-19 Convalescent Plasma
2
Placebo
0
Mechanical Ventilation or Death EndpointSecondary· Day 28
Progression to mechanical ventilation or death within the first 28 days of enrollment.
Group
Value
95% CI
COVID-19 Convalescent Plasma
2
Placebo
0
8-Point Ordinal Scale EndpointSecondary· Day 29
Clinical efficacy of CCP relative to the control arm in adults hospitalized with COVID-19 according to clinical status as assessed by 8-point ordinal scale.
8 Point WHO Ordinal Scale of Clinical Status:
Uninfected (No clinical or virological evidence of infection) - 0
Ambulatory (No limitation of activities) - 1 Ambulatory (Limitation of Activities) - 2
Hospitalized Mild Disease (Hospitalized, no oxygen therapy) - 3 Hospitalized Mild Disease (Oxygen by mask or nasal prongs) - 4
Hospitalized Severe Disease (Non-invasive ventilation or high flow oxygen) - 5 Hospitalized Severe Disease (Intu
Day 1
Group
Value
95% CI
COVID-19 Convalescent Plasma
2.43
1 – 4
Placebo
1.93
1 – 3
Day 2
Group
Value
95% CI
COVID-19 Convalescent Plasma
2.15
1 – 4
Placebo
2.14
1 – 3.75
Day 3
Group
Value
95% CI
COVID-19 Convalescent Plasma
3.92
3 – 4
Placebo
4
4 – 4
Day 4
Group
Value
95% CI
COVID-19 Convalescent Plasma
3.42
3 – 4
Placebo
3.69
3.5 – 4
Day 5
Group
Value
95% CI
COVID-19 Convalescent Plasma
2.83
1 – 4
Placebo
2.92
2.5 – 4
Day 6
Group
Value
95% CI
COVID-19 Convalescent Plasma
2.18
0.5 – 3.5
Placebo
2.45
0 – 4
Day 7
Group
Value
95% CI
COVID-19 Convalescent Plasma
3.4
1 – 5
Placebo
3.5
3 – 4
Day 8
Group
Value
95% CI
COVID-19 Convalescent Plasma
5
4.5 – 5.5
Placebo
2.57
2 – 3.5
Adverse events — posted to ClinicalTrials.gov
Time frame: 90 days.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
· Phase 1
· active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
· Phase 3
· active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
· Phase 1
· recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
· Phase 2
· recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A
· Phase 3
· active not recruiting
Other Priscilla Hsue, MD trials
Trials by the same sponsor.
NCT05488431 — Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
· Phase 2
· recruiting
NCT04939311 — Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
· Phase 1, PHASE2
· withdrawn
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Priscilla Hsue, MD
Last refreshed: 7 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04421404.